When patient-reported outcomes differ from physician follow-up in cancer care — the role of Patient Support Programs

       According to a study recently published in JAMA Network Open, symptom monitoring through patient-reported outcomes (PROs) was compared in a controlled trial against standard care in which healthcare staff proactively checked in with patients. Lung cancer patients in the trial saw significant improvement in health-related quality of life (HRQOL) in both arms. However, there was no significant difference in effect between patient-initiated reporting and physician-initiated intervention, and no statistically significant difference in overall survival. An extended implication of the study: effective long-term symptom support can be provided to patients without adding to the workload of healthcare staff.

       In cancer care, patient-reported outcomes (PROs) are becoming an important tool for improving patient health outcomes. These online digital reporting tools are increasingly used in clinical practice to improve patients' quality of life and treatment adherence. The recently published SYMPRO-Lung trial was a multicenter randomized controlled study involving 515 patients with stage I to IV lung cancer. It found that symptom monitoring through online PROs significantly improved patients' HRQOL, showing that active patient participation during treatment can produce positive therapeutic effects. However, there was no significant difference between patient-initiated reporting and physician-initiated care intervention, and no significant improvement in survival was observed.

       Online patient self-reporting systems are also now a common digital tool in PSPs (Patient Support Programs), helping healthcare staff carry out surveys, improve treatment adherence, and keep the medical team informed of patient status. The digital PSP management platform that PatientsForce currently provides likewise includes a module for regular patient self-reporting, combined with personalized push notifications that keep patients engaged through regular touchpoints. For pharmaceutical companies, promoting the broad adoption of PROs and PSPs not only improves patient outcomes but also relieves pressure on the healthcare system and supports clinical decision-making.

       Patient-reported outcomes and Patient Support Programs are indispensable components of modern cancer care. Healthcare institutions and drug providers play a key role in driving adoption of these tools — improving not only patients' quality of life but also the problem of overwork in healthcare organizations.
 

─ Sean Chang, General Manager, PatientsForce Media-WIND Health Group (MWHG)